Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype

References

• Miller T. P., Lippman S. M., Spier C. M. HLA-DR (la) Immune phenotype predicts outcome for patients with diffuse large cell lymphoma. Journal of Clinical Investigation 1988; 82: 370–372
   PubMed Web of Science ®Google Scholar
• Tanaka K., Yoshioka T., Bieberich C. Role of the major histocompatibility complex Class I antigens in tumor growth and metastasis. Annual Revue of Immunology 1988; 6: 359–380
   PubMed Web of Science ®Google Scholar
• Clayberger C., Medeiros L. J., Link M. Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Lancet 1987; ii: 533–536
   Google Scholar
• Warnke R., Levy R. Detection of T and B cell antigens with hybridoma monoclonal antibodies: A biotinavidin horseradish peroxidase method. Journal of Histochemistry and Cytochemistry 1980; 28: 771–777
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K. Report of the committee on Hodgkin's disease staging classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Jones S. E., Grozea P. N., Miller T. P. Chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone alone or with levamisole. Journal of Clinical Oncology 1985; 3: 1318–1324
   PubMed Web of Science ®Google Scholar
• Miller T. P., Jones S. E. Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 1983; 62: 413–418
   PubMed Web of Science ®Google Scholar
• Skarin A., Canellos G., Rosenthal D. Moderate dose methotrexate combined bleomycin, Adriamycin, cyclophosphamide, oncovin and dexamethasone, m-BACOD, in advanced diffuse histiocytic lymphoma. Proceedings of the American Society of Clinical Oncology 1983; 2: 220, (abstr)
   Google Scholar
• Fisher R. I., DeVita V. T., Hubbard S. M. Randomized trial of ProMACE-MOPP vs ProMACE-CytaBOM in previously untreated advanced stage, diffuse aggressive lymphomas. Proceedings of the American Society of Clinical Oncology 1984; 3: 242, (abstr)
   Google Scholar
• Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Annals of Internal Medicine 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 1966; 50: 163–170
   PubMedGoogle Scholar
• Möller P., Herrmann B., Moldenhauer G. Defective expression of MHC Class I antigens is frequent in B-cell lymphomas of higher-grade malignancy. International Journal of Cancer 1987; 40: 32–39
   PubMed Web of Science ®Google Scholar
• Momburg F., Herrmann B., Moldenhauer G. B-cell lymphomas of highgrade malignancy frequently lack HLA-DR, -DP and DQ antigens and associated invariant chain. International Journal of Cancer 1987; 40: 598–603
   PubMed Web of Science ®Google Scholar
• Bodmer J., Tonks S., Oza A. HLA-DP based resistance to Hodgkin's disease. Lancet 1989; i: 1455–1456
   Google Scholar
• Degener T., Momburg F., Möller P. Differential expression of HLA-DR, HLA-DP, HLA-DQ and associated invariant chain (li) in normal colorectal mucosa, adenoma and carcinoma. Virchows Archiv A Pathological Anatomy and Histopathology 1988; 412: 315–322
   PubMedGoogle Scholar
• Doyle A., Martin J., Funa K. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. Journal of Experimental Medicine 1985; 161: 1135–1151
   PubMed Web of Science ®Google Scholar
• Zaloudik J., Moore M., Ghosh A. DNA content and MHC class II antigen expression in malignant melanoma: clinical course. Journal of Clinical Pathology 1988; 41: 1078–1084
   PubMed Web of Science ®Google Scholar
• van Duinen S., Ruiter D., Broeker E. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Research 1988; 48: 1019–1025
   PubMed Web of Science ®Google Scholar
• Herlyn M., Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significant. Annual Revue of Immunology 1988; 6: 283–308
   PubMed Web of Science ®Google Scholar
• Guerry D., Alexander M., Herlyn M. HLA-DR histocompatible leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. Journal of Clinical Investigation 1984; 73: 267–271
   PubMed Web of Science ®Google Scholar
• Fossati G., Taramelli D., Dalsar A. Primary but not metastatic human melanoma expressing DR antigens stimulate autologous lymphocytes. International Journal of Cancer 1984; 33: 591–597
   PubMed Web of Science ®Google Scholar
• Funa K., Gazdar A. F., Mattson K. Interferon-mediated in vivo induction of beta-2-microglobulin on small-cell lung cancers and mid-gut carcinoids. Clinical Immunology and Immunopathology 1986; 41: 159–164
   PubMedGoogle Scholar
• Mattson K., Holsti L. R., Niiranen A. Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer. Journal of Biological Response Modifiers 1985; 4: 8–17
   PubMedGoogle Scholar
• Marley G. M., Doyle L. A., Ordonez J. V. Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer. Cancer Research 1989; 49: 6232–6236
   PubMed Web of Science ®Google Scholar
• Lippman S. M., Spier C. M., Miller T. M. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma. Modern Pathology 1990; 3: 361–367
   PubMed Web of Science ®Google Scholar
• Lippman S. M., Miller T. P., Spier C. M. The prognostic significance of the immunophenotype in diffuse large cell lymphoma: A comparative study of the T-cell and B-cell phenotype. Blood 1988; 72: 436–441
   PubMed Web of Science ®Google Scholar
• Spier C. M., Grogan T. M., Lippman S. M. The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma. American Journal of Pathology 1988; 132: 118–126
   Google Scholar
• Grogan T. M., Lippman S. M., Spier C. M. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988; 71: 1157–1160
   PubMed Web of Science ®Google Scholar
• Slymen D. J., Miller T. P., Lippman S. M. Immunobiologic factors predictive of clinical outcome in diffuse large cell lymphoma. Journal of Clinical Oncology 1990; 8: 986–993
   PubMed Web of Science ®Google Scholar